AbbVie: A Model of Continuous Innovation and Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy ABBV?
Source: Fool
- Company Background: AbbVie was spun off from Abbott Labs 13 years ago and has since become the third-largest healthcare company globally, with a market cap of $390 billion, highlighting its significant industry presence.
- Dividend King Status: AbbVie is classified as a Dividend King, having increased its dividends for 50 consecutive years, with an attractive forward dividend yield of 3.1%, making its stock appealing to long-term investors.
- R&D Pipeline: AbbVie boasts approximately 90 clinical development programs, with around 60 in mid- to late-stage studies, indicating its strong capability in innovative drug development, particularly with standout autoimmune drugs like Skyrizi and Rinvoq.
- Strong Adaptability: Since its establishment in 1888, AbbVie has faced numerous challenges, including the patent expiration of Humira, yet it has achieved robust growth through R&D investments and strategic acquisitions, demonstrating its potential for sustained development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 222.440
Low
218.00
Averages
253.26
High
289.00
Current: 222.440
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie: A Model of Continuous Innovation and Growth
- Company Background: AbbVie was spun off from Abbott Labs 13 years ago and has since become the third-largest healthcare company globally, with a market cap of $390 billion, highlighting its significant industry presence.
- Dividend King Status: AbbVie is classified as a Dividend King, having increased its dividends for 50 consecutive years, with an attractive forward dividend yield of 3.1%, making its stock appealing to long-term investors.
- R&D Pipeline: AbbVie boasts approximately 90 clinical development programs, with around 60 in mid- to late-stage studies, indicating its strong capability in innovative drug development, particularly with standout autoimmune drugs like Skyrizi and Rinvoq.
- Strong Adaptability: Since its establishment in 1888, AbbVie has faced numerous challenges, including the patent expiration of Humira, yet it has achieved robust growth through R&D investments and strategic acquisitions, demonstrating its potential for sustained development.
See More
AbbVie Sues HHS Over Botox Price Control Regulations
- Legal Challenge: AbbVie filed a lawsuit against the U.S. Department of Health and Human Services in federal court, contesting the Centers for Medicare & Medicaid Services' (CMS) decision to impose price controls on Botox, arguing that this violates the exclusion established by Congress in the Inflation Reduction Act of 2022.
- Product Classification Dispute: AbbVie claims that one-third of Botox consists of human serum albumin, a protein derived from human plasma that is essential for the product's safety and efficacy, thus categorizing it as a 'plasma-derived product' exempt from price controls.
- Financial Impact Assessment: Botox accounted for over 10% of AbbVie's $61.16 billion revenue last year, with therapeutic purchases making up about 6%, and the price controls could force the company to sell at 'confiscatory prices', jeopardizing profitability and market position.
- Constitutional Rights Argument: AbbVie asserts that CMS's actions violate its First Amendment rights by dictating how it must communicate pricing, and also constitute a due process violation and illegal 'taking' under the Fifth Amendment, seeking to end the imposed price controls.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
High Dividend ETFs Offer Stability for Investors
- Risk Assessment: The recent volatility in silver and gold prices has increased investor risk, making traditional safe-haven assets less ideal for risk-averse investors.
- ETF Investment Benefits: The iShares Core High Dividend ETF focuses on high-quality dividend stocks, holding around 75 selectively chosen stocks to ensure sustainable payouts, thereby reducing investment risk.
- Yield and Fee Analysis: This ETF offers an annual yield of approximately 3%, nearly three times that of the S&P 500, with an expense ratio of just 0.08%, resulting in only $8 in fees per year on a $10,000 investment, significantly enhancing net returns.
- Long-Term Investment Strategy: With its combination of high yield, low fees, and quality dividend stocks, the iShares Core High Dividend ETF is an ideal choice for long-term investors looking to mitigate market risks, applicable not only in the current environment but also for future investment strategies.
See More
Gold and Silver Investment Risks Increase Amid Volatility
- Increased Investment Risks: Recent volatility in gold and silver prices has heightened risks for investors, particularly for risk-averse individuals, as the increased speculation surrounding these traditionally safe assets complicates investment decisions.
- ETF Investment Advantages: Investors are encouraged to consider high-dividend exchange-traded funds (ETFs) like the iShares Core High Dividend ETF (HDV), which offers a yield of approximately 3%, significantly higher than the S&P 500's 1.1%, and features a low expense ratio of just 0.08%, ensuring that long-term returns are not eroded by high fees.
- Quality Stock Portfolio: The iShares ETF comprises around 75 carefully selected stocks, including high-quality companies like ExxonMobil, AbbVie, and Coca-Cola, which have strong financial health and can provide sustainable dividends, thereby reducing investment risk.
- Long-Term Investment Strategy: In the current market environment, opting for low-fee, high-yield ETFs like the iShares Core High Dividend ETF can help investors achieve a stable income stream amidst uncertainty, making it suitable for long-term investors looking to mitigate risk.
See More
Next-Gen CNS Assets Attract Investor Interest
- Significant Drug Efficacy: Novel serotonergic agonists (NSAs) activate specific serotonin receptors to produce faster and more meaningful results than traditional antidepressants, positioning them to capture a significant share of the $50-60 billion depression and anxiety treatment market, thereby enhancing patient treatment experiences and outcomes.
- Massive Market Potential: The global neuropsychiatric drug market is projected to exceed $150 billion by the end of the decade, and as awareness and acceptance of new serotonin-based therapies increase, NSAs are poised to secure a meaningful slice of this market, driving long-term growth for the company.
- Leadership Transition: Helus Pharma has appointed Michael Cola as CEO, whose extensive experience in neuroscience and global commercialization is expected to accelerate the development of next-generation mental health therapies and expedite the release of clinical data and market entry.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications globally, with more than 100 patents granted, and as the company transitions from early clinical development to later-stage execution, its robust intellectual property portfolio will provide a competitive edge and support future commercialization efforts.
See More
AbbVie: A Model of Continuous Innovation and Growth
- Company Background: AbbVie was spun off from Abbott Labs 13 years ago and has since become the third-largest healthcare company globally, with a market cap of $390 billion, highlighting its significant industry presence.
- Dividend King Status: AbbVie is classified as a Dividend King, having increased its dividends for 50 consecutive years, with an attractive forward dividend yield of 3.1%, making its stock appealing to long-term investors.
- R&D Pipeline: AbbVie boasts approximately 90 clinical development programs, with around 60 in mid- to late-stage studies, indicating its strong capability in innovative drug development, particularly with standout autoimmune drugs like Skyrizi and Rinvoq.
- Strong Adaptability: Since its establishment in 1888, AbbVie has faced numerous challenges, including the patent expiration of Humira, yet it has achieved robust growth through R&D investments and strategic acquisitions, demonstrating its potential for sustained development.
See More
AbbVie Sues HHS Over Botox Price Control Regulations
- Legal Challenge: AbbVie filed a lawsuit against the U.S. Department of Health and Human Services in federal court, contesting the Centers for Medicare & Medicaid Services' (CMS) decision to impose price controls on Botox, arguing that this violates the exclusion established by Congress in the Inflation Reduction Act of 2022.
- Product Classification Dispute: AbbVie claims that one-third of Botox consists of human serum albumin, a protein derived from human plasma that is essential for the product's safety and efficacy, thus categorizing it as a 'plasma-derived product' exempt from price controls.
- Financial Impact Assessment: Botox accounted for over 10% of AbbVie's $61.16 billion revenue last year, with therapeutic purchases making up about 6%, and the price controls could force the company to sell at 'confiscatory prices', jeopardizing profitability and market position.
- Constitutional Rights Argument: AbbVie asserts that CMS's actions violate its First Amendment rights by dictating how it must communicate pricing, and also constitute a due process violation and illegal 'taking' under the Fifth Amendment, seeking to end the imposed price controls.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
High Dividend ETFs Offer Stability for Investors
- Risk Assessment: The recent volatility in silver and gold prices has increased investor risk, making traditional safe-haven assets less ideal for risk-averse investors.
- ETF Investment Benefits: The iShares Core High Dividend ETF focuses on high-quality dividend stocks, holding around 75 selectively chosen stocks to ensure sustainable payouts, thereby reducing investment risk.
- Yield and Fee Analysis: This ETF offers an annual yield of approximately 3%, nearly three times that of the S&P 500, with an expense ratio of just 0.08%, resulting in only $8 in fees per year on a $10,000 investment, significantly enhancing net returns.
- Long-Term Investment Strategy: With its combination of high yield, low fees, and quality dividend stocks, the iShares Core High Dividend ETF is an ideal choice for long-term investors looking to mitigate market risks, applicable not only in the current environment but also for future investment strategies.
See More
Gold and Silver Investment Risks Increase Amid Volatility
- Increased Investment Risks: Recent volatility in gold and silver prices has heightened risks for investors, particularly for risk-averse individuals, as the increased speculation surrounding these traditionally safe assets complicates investment decisions.
- ETF Investment Advantages: Investors are encouraged to consider high-dividend exchange-traded funds (ETFs) like the iShares Core High Dividend ETF (HDV), which offers a yield of approximately 3%, significantly higher than the S&P 500's 1.1%, and features a low expense ratio of just 0.08%, ensuring that long-term returns are not eroded by high fees.
- Quality Stock Portfolio: The iShares ETF comprises around 75 carefully selected stocks, including high-quality companies like ExxonMobil, AbbVie, and Coca-Cola, which have strong financial health and can provide sustainable dividends, thereby reducing investment risk.
- Long-Term Investment Strategy: In the current market environment, opting for low-fee, high-yield ETFs like the iShares Core High Dividend ETF can help investors achieve a stable income stream amidst uncertainty, making it suitable for long-term investors looking to mitigate risk.
See More
Next-Gen CNS Assets Attract Investor Interest
- Significant Drug Efficacy: Novel serotonergic agonists (NSAs) activate specific serotonin receptors to produce faster and more meaningful results than traditional antidepressants, positioning them to capture a significant share of the $50-60 billion depression and anxiety treatment market, thereby enhancing patient treatment experiences and outcomes.
- Massive Market Potential: The global neuropsychiatric drug market is projected to exceed $150 billion by the end of the decade, and as awareness and acceptance of new serotonin-based therapies increase, NSAs are poised to secure a meaningful slice of this market, driving long-term growth for the company.
- Leadership Transition: Helus Pharma has appointed Michael Cola as CEO, whose extensive experience in neuroscience and global commercialization is expected to accelerate the development of next-generation mental health therapies and expedite the release of clinical data and market entry.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications globally, with more than 100 patents granted, and as the company transitions from early clinical development to later-stage execution, its robust intellectual property portfolio will provide a competitive edge and support future commercialization efforts.
See More
